Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Upcoming Virtual Investor Event

Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors Monday, November 14th at 5:00 PM ET WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc....
November 03, 2022 09:34 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
October 05, 2022 08:33 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
September 22, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
September 12, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

Financing supports management’s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche extends cash runway into the second quarter of 2024 WALTHAM, Mass., Sept. 12,...
September 07, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
August 10, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs ...
August 03, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
July 11, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to neoadjuvant immunotherapy TCR for...
July 07, 2022 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer

WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...